4.2 Article

Cardiovascular complications after transplantation: Treatment options in solid organ recipients

期刊

TRANSPLANTATION REVIEWS
卷 28, 期 2, 页码 47-55

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.trre.2013.12.001

关键词

-

资金

  1. Sanofi Aventis
  2. Novartis
  3. Merke Sharpe Dome
  4. Astellas

向作者/读者索取更多资源

Premature cardiovascular disease is the commonest cause of death in solid organ transplant recipients, with coronary artery disease, sudden cardiac death and heart failure being highly prevalent. There are unique factors leading to CV disease in organ transplant recipients that include underlying comorbidities, and metabolic effects of immunosuppression. As a consequence management strategies developed in the general population may have limited benefit. In this review, we will focus on renal transplantation, where most research has been carried out and, despite incomplete understanding of the disease process, the incidence of cardiovascular disease appears to be falling. (C) 2014 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据